Deals this week: Odonate Therapeutics, China Reform Holdings, Denali Therapeutics

1st December 2017 (Last Updated December 1st, 2017 00:00)

US-based therapeutics developer Odonate Therapeutics LLC plans to raise $182.57m through an initial public offering (IPO) of 6,762,000 shares of its common stock priced at $27 a share.

US-based therapeutics developer Odonate Therapeutics LLC plans to raise $182.57m through an initial public offering (IPO) of 6,762,000 shares of its common stock priced at $27 a share.

Goldman Sachs and Co LLC, Jefferies LLC, and Cowen and Company LLC will serve as underwriters for the funding, while Gibson, Dunn and Crutcher LLP will serve as legal advisor to Odonate.

The company plans to use the funds for conducting a clinical study named CONTESSA on the drug tesetaxel. CONTESSA will be a multi-national, multi-centre, randomised, phase III clinical study conducted on patients with metastatic breast cancer (MBC). Part of the proceeds will also be used for other clinical studies and manufacturing activities of tesetaxel.

Private equity firm China Reform Holdings Corp Ltd has invested $101.2m in a Chinese clinical diagnosis and drug discovery company named 3D Medicines Corp.

The investment was made through the state-owned Assets Venture Investment Fund and other investors.

Denali Therapeutics Inc plans to raise $182.08m through an IPO of 9,583,333 shares of its common stock priced at $19 a share.

Goldman Sachs and Co LLC, Morgan Stanley and Co LLC, JP Morgan Securities LLC, and Evercore Group LLC will serve as underwriters for the IPO, while Wilson Sonsini Goodrich and Rosati will serve as a legal advisor.

The US-based therapeutics company plans to use the funds towards Phase I trials on DNL201 and DNL151, and Phase Ib study on patients with LRRK2 mutation-carrying Parkinson’s disease. Part of the proceeds will also be used for RIPK1 programme via Phase I and early Phase II clinical development.

"Medeor intends to develop MDR-103 and MDR-104 for induction of delayed immune tolerance and for the needs of deceased donor kidney transplant patients respectively."

Medeor Therapeutics Inc has secured $57m in a series B venture funding round led by RA Capital Management LLC.

The company will use the funds to finance phase III clinical trial of MDR-101 and phase 2b trial of MDR-102 in living donor HLA-matched kidney transplant patients.

Medeor intends to develop MDR-103 and MDR-104 for induction of delayed immune tolerance and for the needs of deceased donor kidney transplant patients respectively.

Catalyst Pharmaceuticals Inc plans to raise $50m through a public offering of 14,285,715 shares priced at $3.5 a share.

Based in the US, Catalyst is a biopharmaceutical company that develops therapeutics for rare neurological diseases.

The firm will use the funds to support Firdapse’s pre-commercialisation activities, general corporate purposes and clinical studies of Firdapse, a drug that is used for MuSK-antibody positive Myasthenia Gravis and Spinal Muscular Atrophy treatment.

CinRx Pharma LLC has secured $10m from existing and new investors in a series B venture funding round.

Based in the US, CinRx Pharma is a biopharmaceutical company that develops novel therapeutics for addressing unmet medical needs.

The company will use the funds to advance its clinical development pipeline.